Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment

NCT04060394 is registered in ClinicalTrials.gov with Laekna Limited as lead sponsor.

NCT NCT04060394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04060394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
Lead sponsor
Laekna Limited
Phase
Phase 1/2
Overall status
Completed
Start date
September 13, 2019
Completion date
March 30, 2024
Enrollment
49 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer